[go: up one dir, main page]

AR075736A1 - Sal de sodio de acido 5- ciclopropil -2-((2-(2,6- difluorofenil ) pirimidin -5-il) amino) benzoico como inhibidor de dhodh (dihidroorotato deshidrogenasa) - Google Patents

Sal de sodio de acido 5- ciclopropil -2-((2-(2,6- difluorofenil ) pirimidin -5-il) amino) benzoico como inhibidor de dhodh (dihidroorotato deshidrogenasa)

Info

Publication number
AR075736A1
AR075736A1 ARP100100739A ARP100100739A AR075736A1 AR 075736 A1 AR075736 A1 AR 075736A1 AR P100100739 A ARP100100739 A AR P100100739A AR P100100739 A ARP100100739 A AR P100100739A AR 075736 A1 AR075736 A1 AR 075736A1
Authority
AR
Argentina
Prior art keywords
difluorophenyl
amino
sodium salt
benzoic
cyclopropil
Prior art date
Application number
ARP100100739A
Other languages
English (en)
Inventor
Laurent Debethune
Carrera Francesc Carrera
Gonzalez Nuria Garcia
Masia Xavier Serra
Jane Montserrat Julia
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40903239&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR075736(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of AR075736A1 publication Critical patent/AR075736A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se refiere a la sal de sodio cristalina hidrosoluble de ácido 2-{[5-ciclopropil-2-{[2-(2,6'-difluorofenil)pirimidin-5-il]amino}benzoico y a sus solvatos farmacéuticamente aceptables, composiciones farmacéuticas, composiciones utiles para artritis reumatoidea, psoriásica, espondilitis anquilosante, etc.
ARP100100739A 2009-03-13 2010-03-11 Sal de sodio de acido 5- ciclopropil -2-((2-(2,6- difluorofenil ) pirimidin -5-il) amino) benzoico como inhibidor de dhodh (dihidroorotato deshidrogenasa) AR075736A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09382033A EP2239256A1 (en) 2009-03-13 2009-03-13 Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor

Publications (1)

Publication Number Publication Date
AR075736A1 true AR075736A1 (es) 2011-04-20

Family

ID=40903239

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100739A AR075736A1 (es) 2009-03-13 2010-03-11 Sal de sodio de acido 5- ciclopropil -2-((2-(2,6- difluorofenil ) pirimidin -5-il) amino) benzoico como inhibidor de dhodh (dihidroorotato deshidrogenasa)

Country Status (22)

Country Link
US (1) US8501943B2 (es)
EP (2) EP2239256A1 (es)
JP (1) JP2012520250A (es)
KR (1) KR20110125653A (es)
CN (1) CN102348687B (es)
AR (1) AR075736A1 (es)
AU (1) AU2010223526A1 (es)
CA (1) CA2754801A1 (es)
CL (1) CL2011002215A1 (es)
CO (1) CO6420336A2 (es)
EA (1) EA020218B1 (es)
EC (1) ECSP11011383A (es)
IL (1) IL214518A0 (es)
MX (1) MX2011009148A (es)
NZ (1) NZ594492A (es)
PE (1) PE20120114A1 (es)
SG (1) SG173825A1 (es)
TW (1) TW201032811A (es)
UA (1) UA105788C2 (es)
UY (1) UY32466A (es)
WO (1) WO2010102824A2 (es)
ZA (1) ZA201105742B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2376495A4 (en) 2008-12-08 2012-10-31 Vm Pharma Llc COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
EP2444088A1 (en) * 2010-10-22 2012-04-25 Almirall, S.A. Amino derivatives for the treatment of proliferative skin disorders
US20120195933A1 (en) * 2011-01-27 2012-08-02 Ralph Stefan Pharmaceutical compositions comprising tasocitinib
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
MX2017003439A (es) 2014-09-17 2017-12-04 Mundipharma International Corporation Ltd Formas cristalinas de inhibidores de tirosina cinasa y sus sales.
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
CN114957650B (zh) * 2022-06-11 2024-05-10 新疆腾域鸿源农业科技有限公司 一种聚天冬氨酸钾的制备方法及其在植物生长促进剂中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9608997A (pt) 1995-06-21 1999-06-29 Asta Medica Ag Cartucho para pó farmacêutico com dispositivo de medição integrado e intalador para medicamentos em pó
DE19547648A1 (de) 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9804343D0 (en) 1998-02-27 1998-04-22 Univ Cardiff Chemical compounds
CN1378446A (zh) 1999-06-10 2002-11-06 华纳一兰伯特公司 抑制淀粉样蛋白聚集和使淀粉样沉积物成象的方法
EP1935416A3 (en) 2001-04-05 2008-10-22 Aventis Pharma Inc (Z) -2-cyano-3-hydroxybut-2-enoic acid (4'-trifluoromethylphenyl) amide for the treatment of multiple sclerosis
PE20030120A1 (es) 2001-06-19 2003-02-12 Merck & Co Inc Sal amina de un antagonista de receptor de integrin
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
AR042206A1 (es) 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
WO2004056746A1 (en) 2002-12-23 2004-07-08 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
AU2003300530A1 (en) 2002-12-23 2004-07-14 4Sc Ag Dhodh-inhibitors and method for their identification
SE0400234D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New compounds, methods for their preparation and use thereof
JP2008500393A (ja) 2004-05-21 2008-01-10 ザ ユーエービー リサーチ ファンデーション ピリミジン合成インヒビターに関する組成物および方法
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2006044741A1 (en) 2004-10-19 2006-04-27 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2303758B1 (es) 2006-02-20 2009-08-13 Laboratorios Almirall S.A. Nuevos derivados de piridin-3-amina.
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
DE602008006679D1 (de) 2007-02-06 2011-06-16 Chelsea Therapeutics Inc Neue verbindungen, verfahren zu deren herstellung und deren verwendung
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2210615A1 (en) 2009-01-21 2010-07-28 Almirall, S.A. Combinations comprising methotrexate and DHODH inhibitors
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid

Also Published As

Publication number Publication date
SG173825A1 (en) 2011-09-29
WO2010102824A3 (en) 2010-11-18
UA105788C2 (uk) 2014-06-25
CN102348687A (zh) 2012-02-08
MX2011009148A (es) 2011-09-28
EP2406221A2 (en) 2012-01-18
CA2754801A1 (en) 2010-09-16
KR20110125653A (ko) 2011-11-21
CL2011002215A1 (es) 2012-03-09
EA020218B1 (ru) 2014-09-30
PE20120114A1 (es) 2012-02-20
ECSP11011383A (es) 2011-11-30
IL214518A0 (en) 2011-09-27
EA201101301A1 (ru) 2012-04-30
UY32466A (es) 2010-09-30
EP2239256A1 (en) 2010-10-13
WO2010102824A2 (en) 2010-09-16
JP2012520250A (ja) 2012-09-06
AU2010223526A1 (en) 2011-08-25
NZ594492A (en) 2013-11-29
ZA201105742B (en) 2012-04-25
US8501943B2 (en) 2013-08-06
CN102348687B (zh) 2014-04-02
US20120003184A1 (en) 2012-01-05
CO6420336A2 (es) 2012-04-16
TW201032811A (en) 2010-09-16

Similar Documents

Publication Publication Date Title
AR075736A1 (es) Sal de sodio de acido 5- ciclopropil -2-((2-(2,6- difluorofenil ) pirimidin -5-il) amino) benzoico como inhibidor de dhodh (dihidroorotato deshidrogenasa)
AR114946A2 (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
MX2013005533A (es) Derivados de acido amino-bisfenil-pentanoico sustituidos como inhibidores de nep.
NZ607845A (en) Besylate salt of a btk inhibitor
PE20120171A1 (es) Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acidos aminonicotinico como inhibidores de dhodh
CL2011002918A1 (es) Composicion farmaceutica solida que comprende al inhibidor de quinasa aurora acido 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoico, una sal o una forma cristalina del mismo; metodo para prepararla que incluye un proceso de granulacion en humedo.
UY33044A (es) Derivados del acido carbamoil-metil-amino-acetico sustituido como inhibidores de nep novedosos
PA8855501A1 (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
MY152281A (en) 4-pyrimidinesulfamide derivative
ECSP099565A (es) Compuesto de 2-amino pirimidina
CL2011002213A1 (es) Sal de adicion cristalina de (i) trometamina con (ii) un derivado de acido azabifenilaminobenzoico; composicion farmaceutica que comprende a la sal y otros agentes terapeuticos; combinacion farmaceutica; y su uso para el tratamiento de artritis reumatoide, artritis psoriasica, espondilitis anquilosante, esclerosis multiple, entre otras
PT2448933E (pt) Ácido trans-4-[[(5s)-5-[[[3,5- bis(trifluorometil)fenil]metil] (2-metil-2h-tetrazol-5- il)amino]-2,3,4,5-tetra-hidro-7,9-dimetil-1h-1-benzazepin- 1-il]metil]-ciclo-hexanocarboxílico
PH12014502210A1 (en) Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one
TN2009000167A1 (en) Crystalline potassium salt of lipoxin a4 analogs
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
NZ610765A (en) Method for the preparation of high-purity pharmaceutical intermediates
IL200323A0 (en) Synthesis of glyt-1 inhibitors
MX340076B (es) Proceso de preparacion de sales herbicidas.
CL2013000578A1 (es) Sal cristalina de sodio del acido (e)-3-[2-(1-{[2-(5-bromo-pririmidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilico: sal amorfa;compuestos intermediarios; procedimientos de preparacion; composicion farmaceutica.
FR2984319B1 (fr) Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
PA8786301A1 (es) "un nuevo procedimiento para preparar acido 2-(3-{6-[2(2,4-diclorofenil)-etilamino]-2-metoxipirimidin-4-il}-fenil)-2-metil-propionico"
TH133899A (th) เกลือโซเดียมของกรด 5-ไซโคลโพรพิล-2-{[2-(2,6-ไดฟลูออโรฟีนิล)ไพริมิดิน-5-อิล]อะมิโน}เบนโซอิค ในฐานะเป็นสารยับยั้ง dhodh
FR2984320B1 (fr) Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2911338B1 (fr) Nouveau procede de preparation de derives d'amino-acides insatures

Legal Events

Date Code Title Description
FA Abandonment or withdrawal